U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.00
    -3.70 (-0.21%)
     
  • Silver

    22.38
    -0.42 (-1.84%)
     
  • EUR/USD

    1.1729
    -0.0043 (-0.36%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3730
    -0.0066 (-0.48%)
     
  • USD/JPY

    109.9720
    +0.2540 (+0.23%)
     
  • BTC-USD

    47,175.14
    -172.11 (-0.36%)
     
  • CMC Crypto 200

    1,194.60
    -30.93 (-2.52%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Is It Too Late to Buy Fulgent Genetics Stock?

·3 min read
Is It Too Late to Buy Fulgent Genetics Stock?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

What's more, the company has about $697.4 million in cash on its balance sheet and negligible debt. Subtract that from the company's $2.43 billion market cap, and Fulgent appears even more undervalued in terms of its enterprise value (EV). After all, the company is heavily dependent on providing billable COVID-19 tests in the U.S., where the pandemic is largely subsiding as the government's mass vaccination campaign has successfully inoculated more than half of all adults already.